We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.025 | -3.70% | 0.65 | 0.60 | 0.70 | 0.675 | 0.625 | 0.675 | 1,668,891 | 16:20:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.14 | 1.18M |
TIDMN4P
RNS Number : 9917S
N4 Pharma PLC
15 July 2020
15 July 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Change of Adviser
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce the appointment of SP Angel Corporate Finance LLP as the Company's Nominated Adviser and Joint Broker, with immediate effect.
Management Change
The Company also announces that Luke Cairns, previously a Non-Executive Director of the Company, has been appointed to an Executive Director position. Luke will be overseeing the Company's finance and investor relations activities, thereby allowing Nigel Theobald, Chief Executive Officer, more time to focus on driving the Company's development programmes and potential commercial collaborations.
Enquiries:
N4 Pharma plc Nigel Theobald, CEO Via Scott PR Luke Cairns, Executive Director SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470 Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657 0050 Joint Broker Andy Thacker Scott PR Georgia Smith Tel: +44(0)1477 539 539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
APPRIMITMTJBBMM
(END) Dow Jones Newswires
July 15, 2020 02:00 ET (06:00 GMT)
1 Year N4 Pharma Chart |
1 Month N4 Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions